#Andamertinib
LightNews LightNews
dengyuemedicine.bsky.social
China aprueba Andamertinib para NSCLC EGFR Exon 20 🇨🇳

Nuevo EGFR-TKI de 3ª generación.

🔬
• Irreversible
• Penetración SNC
• Actividad clínica observada

#Andamertinib #NSCLC #EGFRTKI #Oncology #DengYueMed
May 7, 2026 at 7:06 AM
longtail-news.bsky.social
Feed: "Business-News-Today.com"
By: Pallavi Madhiraju on Sunday, June 1, 2025
Avistone Biotechnology presents positive ASCO 2025 results for dual inhibitor therapy in EGFR-mutated NSCLC
Avistone reveals 50% ORR and 9.9-month PFS for its Vebreltinib–Andamertinib combo in MET-amplified NSCLC at ASCO 2025. Find out what this means for lung cancer care.
business-news-today.com
June 1, 2025 at 6:19 PM
drtimos.bsky.social
Thoughts on this? >> Avistone Announces Encouraging Results for Vebreltinib plus
Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification
or Overexpression at ASCO Annual Meeting 2025 >> Comment below! #IoT #healthtech #industry40 #mhealth #AI
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING–(BUSINESS WIRE)–Beijing Avistone Biotechnology Co., Ltd (“Avistone”), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of …
dlvr.it
May 31, 2025 at 8:36 PM